Published 3 days ago • loading... • Updated 3 days ago

FDA Approves F8 Formulation of Theratechnologies' Tesamorelin for HIV-Associated Lipodystrophy

Summary

Theratechnologies Inc., a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin for injection. The company will commercialize the new formulation under the trade name EGRIFTA WR™.

9 Articles

All

Left

Center

Right

The Hamilton Spectator

+7 Reposted by 7 other sources

Lean Left

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

New, improved formulation set to replace EGRIFTA SV®

3 days ago·Hamilton, Canada

Read Full Article

contagionlive.com

FDA Approves F8 Formulation of Theratechnologies' Tesamorelin for HIV-Associated Lipodystrophy

Theratechnologies' new tesamorelin formulation provides a simplified, long-acting dosing regimen to effectively manage excess abdominal fat in adults with HIV-associated lipodystrophy.

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year